Drug Profile
Research programme: radiolabelled antagonistic peptides - Ipsen
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator OctreoPharm Sciences
- Class Peptides; Radiopharmaceuticals
- Mechanism of Action Somatostatin receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuroendocrine tumours